Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the <scp>OPERA</scp> cohort
In this large US cohort, both B/F/TAF and DTG/3TC were well tolerated and effective treatment options among virologically suppressed individuals in routine clinical care, although DTG/3TC tended to be discontinued faster than B/F/TAF.
Authors
- Michael Sension
- Jennifer S Fusco (ORCID: https://orcid.org/0000-0003-1556-811X)
- Douglas T. Dieterich (ORCID: https://orcid.org/0000-0001-7786-8594)
- Joshua Gruber
- Gerald Pierone (ORCID: https://orcid.org/0000-0003-0159-7243)
- Laurence Brunet (ORCID: https://orcid.org/0000-0001-8467-4835)
- Megan S. Dunbar (ORCID: https://orcid.org/0000-0001-9250-5126)
- Gregory Fusco (ORCID: https://orcid.org/0000-0002-6834-784X)
Institutions
- Mount Sinai Health System (US)
- Henderson Behavioral Health (US)
- Oyster Point Family Health Center (US)
- Gilead Sciences (United States) (US)
- GridBridge (United States) (US)
Publication Details
- Journal
- HIV Medicine
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1111/hiv.70105
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AIDS Healthcare Foundation
- Gilead Sciences
- ViiV Healthcare
- Janssen Scientific Affairs
- National Institutes of Health
- EMD Serono